Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHST BioHarvest Sciences	$9.11 +3.3%	$7.21	$4.66 ▼ $9.50	$149.59M	0.68	15,215 shs	9,154 shs
CNTB Connect Biopharma	$2.27 +10.7%	$1.41	$0.51 ▼ $2.86	$126.12M	-0.09	112,057 shs	194,027 shs
FATE Fate Therapeutics	$0.94 +0.1%	$1.19	$0.66 ▼ $4.20	$107.24M	2.24	2.04 million shs	963,557 shs
MURA Mural Oncology	$1.66 +7.1%	$2.39	$0.95 ▼ $4.74	$28.75M	3	2.05 million shs	709,492 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHST BioHarvest Sciences	+0.68%	+14.99%	+22.84%	+34.86%	+881,999,900.00%
CNTB Connect Biopharma	-0.97%	+0.49%	+34.87%	+169.38%	+91.57%
FATE Fate Therapeutics	+1.55%	-11.73%	-18.63%	-6.43%	-72.23%
MURA Mural Oncology	-2.52%	-16.22%	-36.48%	-41.73%	-53.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	3.1846 of 5 stars	3.8	3.0	0.0	0.0	3.8	2.5	0.0
FATE Fate Therapeutics	3.9911 of 5 stars	3.1	2.0	0.0	4.7	2.4	2.5	0.6
MURA Mural Oncology	2.688 of 5 stars	3.3	3.0	0.0	0.0	1.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHST BioHarvest Sciences	3.00	Buy	$13.67	50.02% Upside
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	208.37% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	309.41% Upside
MURA Mural Oncology	2.50	Moderate Buy	$12.00	622.89% Upside

Current Analyst Ratings Breakdown

Latest MURA, FATE, BHST, and CNTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHST BioHarvest Sciences	$25.19M	5.94	N/A	N/A	$0.08 per share	113.88
CNTB Connect Biopharma	$26.03M	4.85	N/A	N/A	$1.67 per share	1.36
FATE Fate Therapeutics	$13.34M	8.05	N/A	N/A	$2.80 per share	0.33
MURA Mural Oncology	N/A	N/A	N/A	N/A	$8.22 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHST BioHarvest Sciences	-$12.91M	-$0.50	N/A	N/A	N/A	-31.30%	-307.04%	-33.21%	N/A
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	8/12/2025 (Estimated)

Latest MURA, FATE, BHST, and CNTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.34	-$0.29	+$0.05	-$0.29	$1.16 million	N/A
8/12/2025	N/A	MURA Mural Oncology	-$1.13	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	BHST BioHarvest Sciences	-$0.1075	-$0.15	-$0.0425	-$0.24	$8.53 million	$8.52 million
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A
5/14/2025	Q1 2025	MURA Mural Oncology	-$2.12	-$1.93	+$0.19	-$1.93	N/A	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHST BioHarvest Sciences	N/A	0.51	0.30
CNTB Connect Biopharma	0.01	10.25	10.25
FATE Fate Therapeutics	N/A	8.81	8.81
MURA Mural Oncology	N/A	2.87	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHST BioHarvest Sciences	N/A
CNTB Connect Biopharma	58.72%
FATE Fate Therapeutics	97.54%
MURA Mural Oncology	80.21%

Insider Ownership

Company	Insider Ownership
BHST BioHarvest Sciences	N/A
CNTB Connect Biopharma	22.60%
FATE Fate Therapeutics	5.51%
MURA Mural Oncology	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHST BioHarvest Sciences	N/A	16.42 million	N/A	N/A
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable

MURA, FATE, BHST, and CNTB Headlines

Recent News About These Companies

Mural Oncology (MURA) to Release Quarterly Earnings on Tuesday

August 11 at 2:28 AM | americanbankingnews.com

Mural Oncology (NASDAQ:MURA) Cut to Strong Sell at Wall Street Zen

August 10 at 2:27 AM | americanbankingnews.com

Colourful mural celebrates 10 years of cancer care at WWL

August 4, 2025 | msn.com

Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

August 4, 2025 | globenewswire.com

Mural Oncology (NASDAQ:MURA) Stock Rating Upgraded by Wall Street Zen

August 4, 2025 | americanbankingnews.com

Artists help pupils and centre users create murals

August 3, 2025 | msn.com

Baltimore honors Henrietta Lacks with community-painted mural

August 2, 2025 | msn.com

Baltimore community comes together to complete Henrietta Lacks mural

August 2, 2025 | wmar2news.comW

Community news: Mural walk, health fair, digital skill lessons

July 28, 2025 | chicagotribune.com

Downtown Raleigh’s history unfolds in a sprawling new mural. Who is on it?

July 28, 2025 | msn.com

New mural inspires student growth on the Eastern Shore

July 28, 2025 | msn.com

Can Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth?

July 23, 2025 | finance.yahoo.com

Minneapolis muralist honors Tuskegee airmen

July 19, 2025 | msn.com

Mural Oncology, Inc.: Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - FinanzNachrichten.de

July 8, 2025 | finanznachrichten.de

Demolition threatens breast cancer mural in 12 Points community

July 5, 2025 | wthitv.comW

Building that features the PINK of Terre Haute wings mural to be demolished

July 4, 2025 | msn.com

'Vibrancy': New murals proposed for Downtown Peoria parking decks

July 3, 2025 | msn.com

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

June 16, 2025 | markets.businessinsider.com

BlackRock discloses 1.64% stake in Mural Oncology

June 13, 2025 | investing.com

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

June 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MURA, FATE, BHST, and CNTB Company Descriptions

BioHarvest Sciences NASDAQ:BHST

$9.11 +0.29 (+3.29%)

As of 03:58 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Connect Biopharma NASDAQ:CNTB

$2.27 +0.22 (+10.73%)

Closing price 04:00 PM Eastern

Extended Trading

$2.38 +0.12 (+5.07%)

As of 07:12 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Fate Therapeutics NASDAQ:FATE

$0.94 +0.00 (+0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$0.96 +0.03 (+2.96%)

As of 07:02 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Mural Oncology NASDAQ:MURA

$1.66 +0.11 (+7.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.66 0.00 (0.00%)

As of 07:06 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time